Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 13/20 | 0.70 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10661457 | 0.91 | MRGPRX4 (0.61) | MRGPRX4SCN9ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL680193 | 0.91 | MRGPRX4 (0.61) | MRGPRX4SCN9ASCN5ASTK39 | |
| SCHEMBL10877691 | 0.88 | CYP1A2 (0.54) | MRGPRX4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11005891 | 0.86 | MRGPRX4 (0.52) | MRGPRX4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL8550325 | 0.84 | MRGPRX4 (0.54) | MRGPRX4 | |
| SCHEMBL11355405 | 0.83 | MRGPRX4 (0.49) | MRGPRX4SCN9ALMNAMAPT | |
| SCHEMBL10673556 | 0.83 | MRGPRX4 (0.67) | MRGPRX4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10613595 | 0.83 | MAOB (0.55) | MRGPRX4CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22481025 | 0.82 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL10656511 | 0.82 | MRGPRX4 (0.52) | MRGPRX4SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070055077-A1 | CHEMICAL PROCESS | SYNGENTA LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| US-20030191341-A1 | Chemical process | BROWN STEPHEN MARTIN (GB) | 2003-10-09 | — | — | US | disclosed |
| EP-0937015-B1 | NITRATION PROCESS | SYNGENTA LTD (GB) | 2001-09-26 | — | — | EP | disclosed |
| EP-0851852-B1 | PROCESS FOR NITRATING DIPHENYL ETHER COMPOUNDS | ZENECA LTD (GB) | 2000-04-05 | — | — | EP | disclosed |
| US-6028219-A | NITRATING WITH A MIXTURE OF NITRIC AND SULPHURIC ACIDS IN THE PRESENCE OF A SOLVENT TETRACHLOROETHYLENE AND IN THE PRESENCE OF ACETIC ANHYDRIDE; CHEMICAL INTERMEDIATES IN THE SYNTHESIS OF HERBICIDES | ZENECA LIMITED (GB) | 2000-02-22 | — | — | US | disclosed |
| US-5952531-A | NITRATION OF AN AROMATIC OR HETEROAROMATIC COMPOUND WITH A NITRATING AGENT COMPRISING NITRIC ACID OR A MIXTURE OF NITRIC AND SULPHURIC ACIDS IN AN ESTER SOLVENT | ZENECA LIMITED (GB) | 1999-09-14 | — | — | US | disclosed |
| EP-0937015-A1 | NITRATION PROCESS | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0668260-B1 | Process for phosgenation in the presence of acetonitrile | ZENECA LTD (GB) | 1998-08-12 | — | — | EP | disclosed |
| US-5792888-A | Process for phosgenation in the presence of acetonitrile | ZENECA LIMITED (GB) | 1998-08-11 | — | — | US | disclosed |
| WO-1998019978-A1 | NITRATION PROCESS | ZENECA LIMITED (GB) | 1998-05-14 | — | — | WO | disclosed |
| EP-0668260-A1 | Process for phosgenation in the presence of acetonitrile | ZENECA LIMITED (GB) | 1995-08-23 | — | — | EP | disclosed |
| EP-0274194-B1 | PROCESS FOR THE PREPARATION OF 2-NITRO-5-PHENOXY-N-ALKYLSULFONYL BENZAMIDES BY NITRATION | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-18 | — | — | EP | disclosed |
| US-4845285-A | Chemical process | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-07-04 | — | — | US | disclosed |
| EP-0274194-A1 | Process for the preparation of 2-nitro-5-phenoxy-N-alkylsulfonyl benzamides by nitration | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055077-A1 | CHEMICAL PROCESS | CBR3, CBR1, CA6 | MRGPRX4 562/4885SCN9A 1484/4885CYP1A2 175/4885 |
| US-20030191341-A1 | Chemical process | CBR1, CBR3, CA4 | MRGPRX4 1087/4885SCN9A 1075/4885CYP1A2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.